- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- Lixisenatide (AVE0010), Lixisenatide Placebo, Pen auto-injector, Sitagliptin, Sitagliptin Placebo, Metformin
- Drug · Device
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years to 49 Years
- Enrollment
- 319 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2011
- U.S. locations
- 21
- States / cities
- Montgomery, Alabama • Muscle Shoals, Alabama • Mesa, Arizona + 17 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 337–360
of 2,222
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Attention Deficit Hyperactivity Disorder (ADHD)
- Interventions
- SHP465 12.5mg, SHP465 25mg
- Drug
- Lead sponsor
- Shire
- Industry
- Eligibility
- 6 Years to 17 Years
- Enrollment
- 27 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015
- U.S. locations
- 3
- States / cities
- Miami, Florida • Las Vegas, Nevada • Houston, Texas
- Conditions
- Partial Epilepsies
- Interventions
- lacosamide
- Drug
- Lead sponsor
- UCB BIOSCIENCES, Inc.
- Industry
- Eligibility
- 16 Years to 70 Years
- Enrollment
- 308 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2009
- U.S. locations
- 60
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 57 more
- Conditions
- Hemophilia A
- Interventions
- Not listed
- Lead sponsor
- Georgetown University
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2010 – 2011
- U.S. locations
- 1
- States / cities
- Washington D.C., District of Columbia
- Conditions
- Aging, Diet, Healthy
- Interventions
- Western Diet
- Other
- Lead sponsor
- University of Delaware
- Other
- Eligibility
- 50 Years to 64 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2027
- U.S. locations
- 1
- States / cities
- Newark, Delaware
- Conditions
- Atherosclerosis, Cardiovascular Disease, Hypercholesterolemia
- Interventions
- VERVE-102, Placebo
- Drug
- Lead sponsor
- Verve Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 175 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 1
- States / cities
- DeSoto, Texas
- Conditions
- Disruptive Behavior Disorders, Conduct Disorder, Oppositional Defiant Disorder, Attention-deficit/Hyperactivity Disorder
- Interventions
- Psychotherapy
- Behavioral
- Lead sponsor
- National Institute of Mental Health (NIMH)
- NIH
- Eligibility
- 8 Years to 13 Years
- Enrollment
- 200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2037
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Chronic Myeloid Leukemia, Chronic Phase, Adult CML, Leukemia, Myeloid, Leukemia,Myeloid, Chronic
- Interventions
- Single Agent Asciminib, Low TKI, Elective Free Treatment
- Drug · Combination Product · Other
- Lead sponsor
- University of Alabama at Birmingham
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2032
- U.S. locations
- 8
- States / cities
- Birmingham, Alabama • Atlanta, Georgia • Augusta, Georgia + 5 more
- Conditions
- Attention Deficit Hyperactivity Disorder, Oppositional Defiant Disorder, Conduct Disorder
- Interventions
- Clinical Assessment Visit, fMRI scan
- Diagnostic Test · Other
- Lead sponsor
- University of Michigan
- Other
- Eligibility
- 6 Years to 18 Years
- Enrollment
- 256 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2019
- U.S. locations
- 1
- States / cities
- Ann Arbor, Michigan
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- Sotagliflozin (SAR439954), Placebo, Metformin
- Drug
- Lead sponsor
- Lexicon Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 518 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2019
- U.S. locations
- 67
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Canoga Park, California + 50 more
- Conditions
- Breast Cancer Female
- Interventions
- OCT- based investigational imaging device
- Device
- Lead sponsor
- Perimeter Medical Imaging
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 58 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2021
- U.S. locations
- 1
- States / cities
- Cottonwood, Arizona
- Conditions
- Schizophrenia
- Interventions
- Aripiprazole, placebo
- Drug
- Lead sponsor
- North Suffolk Mental Health Association
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 16 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2005 – 2007
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Myopia, Hyperopia, Presbyopia
- Interventions
- omafilcon A lens, Low ADD power somofilcon A lens, Medium ADD power somofilcon A lens, High ADD power somofilcon A lens
- Device
- Lead sponsor
- CooperVision International Limited (CVIL)
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 67 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025
- U.S. locations
- 1
- States / cities
- Berkeley, California
- Conditions
- Attention Deficit Hyperactivity Disorder
- Interventions
- Preference and Goal Instrument
- Other
- Lead sponsor
- Children's Hospital of Philadelphia
- Other
- Eligibility
- 6 Years to 12 Years
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2016
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- ADHD
- Interventions
- lisdexamfetamine
- Drug
- Lead sponsor
- Florida International University
- Other
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 38 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2012
- U.S. locations
- 1
- States / cities
- Miami, Florida
- Conditions
- Attention Deficit Disorder With Hyperactivity
- Interventions
- NFC-1 100 mg, NFC-1 200 mg, NFC-1 400 mg, NFC-1 800 mg
- Drug
- Lead sponsor
- Aevi Genomic Medicine, LLC, a Cerecor company
- Industry
- Eligibility
- 6 Years to 17 Years
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017
- U.S. locations
- 3
- States / cities
- Maitland, Florida • Miami, Florida • Las Vegas, Nevada
- Conditions
- Head and Neck Cancer
- Interventions
- Not listed
- Lead sponsor
- Albert Einstein College of Medicine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2026
- U.S. locations
- 1
- States / cities
- The Bronx, New York
- Conditions
- Leukemia
- Interventions
- filgrastim, clofarabine, dexamethasone, thiotepa, topotecan hydrochloride, vinorelbine tartrate
- Biological · Drug
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- Up to 28 Years
- Enrollment
- 23 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2013
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Bipolar Disorder, Cocaine Dependence
- Interventions
- Lamotrigine, Placebo
- Drug
- Lead sponsor
- University of Texas Southwestern Medical Center
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 112 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2010
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Anxiety, PTSD, ADHD, Depression Disorders, Post-traumatic Stress, Substance Use, Executive Function, Sleep Disturbance
- Interventions
- AIP-Informed Integrative Psychotherapy, Transcutaneous Auricular Vagus Nerve Stimulation, Regulated Breathing and Autonomic Regulation, Audiovisual Entrainment, Vibroacoustic Stimulation, Breathwork-Based Auditory Driving Entropy Module (BADEM), Transcranial Electrical Stimulation
- Behavioral · Device
- Lead sponsor
- Tactical Mind Research Coalition, Inc.
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 240 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 1
- States / cities
- Tampa, Florida
- Conditions
- Cystic Fibrosis
- Interventions
- BI 1265162, Placebo
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 52 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2020
- U.S. locations
- 8
- States / cities
- Orlando, Florida • Indianapolis, Indiana • Chapel Hill, North Carolina + 5 more
- Conditions
- Attention-Deficit/Hyperactivity Disorder (ADHD)
- Interventions
- Placebo, 100mg SPN-812, 200mg SPN-812, 300mg SPN-812, 400mg SPN-812
- Drug
- Lead sponsor
- Supernus Pharmaceuticals, Inc.
- Industry
- Eligibility
- 6 Years to 12 Years
- Enrollment
- 222 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016
- U.S. locations
- 1
- States / cities
- Maitland, Florida
- Conditions
- Attention Deficit Hyperactivity Disorder
- Interventions
- Dex-methylphenidate hydrochloride extended-release (Focalin XR), Placebo
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 6 Years to 12 Years
- Enrollment
- 86 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007
- U.S. locations
- 5
- States / cities
- Little Rock, Arkansas • Winter Park, Florida • Las Vegas, Nevada + 2 more
- Conditions
- Alzheimer's Disease
- Interventions
- Rivastigmine, memantine
- Drug
- Lead sponsor
- Novartis
- Industry
- Eligibility
- 50 Years to 85 Years
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2007
- U.S. locations
- 1
- States / cities
- Paterson, New Jersey